R.H. Bluestein & Co’s PAVmed PAVM Stock Holding History

R.H. Bluestein & Co’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29	Closed	-$32K	–	407
2021 Q4	$32K	Hold	29	–	–	﹤0.01%	412
2021 Q3	$111K	Buy	+29	New	+$91.4K	﹤0.01%	415

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

R.H. Bluestein & Co's PAVM Position: Q1 2022 in Review

R.H. Bluestein & Co sold out of PAVmed (PAVM) in Q1 2022, closing a stake of 29 shares — an estimated $32K sold.

R.H. Bluestein & Co first reported a position in PAVM in Q3 2021 and held it in 2 quarters. The position peaked at $111K in Q3 2021. 94 funds tracked by Wall St. Rank hold PAVM as of Q1 2022.

R.H. Bluestein & Co reported no remaining PAVmed position as of Q1 2022 after selling out during the quarter.
R.H. Bluestein & Co sold 29 PAVmed shares in Q1 2022, an estimated $32K.
R.H. Bluestein & Co first reported a position in PAVmed in Q3 2021 and held it in 2 quarters.
R.H. Bluestein & Co's PAVmed position peaked at $111K in Q3 2021.
94 funds tracked by Wall St. Rank held PAVmed as of Q1 2022.

Based on R.H. Bluestein & Co's 13F filing for Q1 2022, filed 11 May 2022.